Mantle cell lymphoma classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Akram}} | {{CMG}}; {{AE}} {{Akram}} | ||
==Overview== | ==Overview== | ||
According to the revised 2016 World Health Organization classification of lymphoid neoplasms, mantle cell lymphoma(MCL) can be broadly classified into three types: | According to the revised 2016 [[World Health Organization]] classification of [[lymphoid]] [[neoplasms]], [[mantle cell lymphoma]] (MCL) can be broadly classified into three types: | ||
#Classical MCL. | #Classical MCL. | ||
#Leukemic nonnodal MCL. | #Leukemic nonnodal MCL. | ||
| Line 11: | Line 11: | ||
=== Classical MCL: === | === Classical MCL: === | ||
* Classical MCL typically develops from immunoglobulin heavy-chain variable region gene(IGHV)-unmutated or minimally mutated B cells that usually express SOX11 (SRY-Box 11 gene).<ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref><ref name="pmid23023712">{{cite journal| author=Jares P, Colomer D, Campo E| title=Molecular pathogenesis of mantle cell lymphoma. | journal=J Clin Invest | year= 2012 | volume= 122 | issue= 10 | pages= 3416-23 | pmid=23023712 | doi=10.1172/JCI61272 | pmc=3461905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23023712 }} </ref> | * Classical MCL typically develops from [[immunoglobulin]] heavy-chain variable region gene(IGHV)-unmutated or minimally [[Mutation|mutated]] [[B cells]] that usually express [[SOX11]] (SRY-Box 11 gene).<ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref><ref name="pmid23023712">{{cite journal| author=Jares P, Colomer D, Campo E| title=Molecular pathogenesis of mantle cell lymphoma. | journal=J Clin Invest | year= 2012 | volume= 122 | issue= 10 | pages= 3416-23 | pmid=23023712 | doi=10.1172/JCI61272 | pmc=3461905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23023712 }} </ref> | ||
* Classical MCL usually involves the lymph nodes and other extranodal sites. | * Classical MCL usually involves the [[lymph nodes]] and other extranodal sites. | ||
* However, these cells can acquire further molecular and cytogenetic abnormalities leading to the more aggressive: | * However, these cells can acquire further [[molecular]] and [[cytogenetic]] abnormalities leading to the more aggressive: | ||
*#Blastoid MCL | *#[[Blastoid]] MCL | ||
*#Pleomorphic MCL | *#[[Pleomorphic]] MCL | ||
=== Leukemic nonnodal MCL: === | === Leukemic nonnodal MCL: === | ||
* Leukemic nonnodal MCL typically develops from immunoglobulin heavy-chain variable region gene(IGHV)-mutated B cells that do not express SOX11 (SRY-Box 11 gene).<ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref><ref name="pmid23023712">{{cite journal| author=Jares P, Colomer D, Campo E| title=Molecular pathogenesis of mantle cell lymphoma. | journal=J Clin Invest | year= 2012 | volume= 122 | issue= 10 | pages= 3416-23 | pmid=23023712 | doi=10.1172/JCI61272 | pmc=3461905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23023712 }} </ref> | * Leukemic nonnodal MCL typically develops from [[immunoglobulin]] heavy-chain variable region gene(IGHV)-[[mutated]] [[B cells]] that do not express [[SOX11]] (SRY-Box 11 gene).<ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref><ref name="pmid23023712">{{cite journal| author=Jares P, Colomer D, Campo E| title=Molecular pathogenesis of mantle cell lymphoma. | journal=J Clin Invest | year= 2012 | volume= 122 | issue= 10 | pages= 3416-23 | pmid=23023712 | doi=10.1172/JCI61272 | pmc=3461905 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23023712 }} </ref> | ||
* Leukemic nonnodal MCL involve the peripheral blood (PB), bone marrow and the spleen. | * Leukemic nonnodal MCL involve the [[peripheral blood]] (PB), [[bone marrow]] and the [[spleen]]. | ||
* Although these are commonly clinically indolent in nature further mutations ,especially of TP53, can lead to more aggressive disease. | * Although these are commonly clinically indolent in nature further mutations ,especially of [[TP53]], can lead to more aggressive disease. | ||
=== In-situ mantle cell neoplasia (ISMCN): === | === In-situ mantle cell neoplasia (ISMCN): === | ||
* It is characterized by the presence of cyclin D1 | * It is characterized by the presence of [[cyclin D1]] positive cells mostly in the inner [[Mantle zone|mantle zones]] of follicles in [[lymphoid]] [[tissues]] that do not otherwise suggest the diagnosis of a MCL.<ref name="pmid22058203">{{cite journal| author=Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY et al.| title=In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. | journal=Haematologica | year= 2012 | volume= 97 | issue= 2 | pages= 270-8 | pmid=22058203 | doi=10.3324/haematol.2011.052621 | pmc=3269489 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058203 }} </ref> | ||
* The in situ lesion stage may be a common step in both SOX11-negative and | * The [[in situ]] lesion stage may be a common step in both [[SOX11]]-negative and positive subtypes of MCL as some in situ lesions express [[SOX11]], whereas others are [[SOX11]] negative.<ref name="pmid20733121">{{cite journal| author=Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM et al.| title=Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. | journal=J Clin Oncol | year= 2010 | volume= 28 | issue= 31 | pages= e629-32 | pmid=20733121 | doi=10.1200/JCO.2010.29.8992 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20733121 }} </ref> | ||
* ISMCN is often found incidentally, occasionally in association with other types of lymphomas. | * ISMCN is often found incidentally, occasionally in association with other types of [[Lymphoma|lymphomas]]. | ||
==References== | ==References== | ||
Revision as of 21:41, 6 November 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma classification On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma classification |
|
Risk calculators and risk factors for Mantle cell lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
According to the revised 2016 World Health Organization classification of lymphoid neoplasms, mantle cell lymphoma (MCL) can be broadly classified into three types:
- Classical MCL.
- Leukemic nonnodal MCL.
- In-situ mantle cell neoplasia (ISMCN).
Classification
Classical MCL:
- Classical MCL typically develops from immunoglobulin heavy-chain variable region gene(IGHV)-unmutated or minimally mutated B cells that usually express SOX11 (SRY-Box 11 gene).[1][2]
- Classical MCL usually involves the lymph nodes and other extranodal sites.
- However, these cells can acquire further molecular and cytogenetic abnormalities leading to the more aggressive:
- Blastoid MCL
- Pleomorphic MCL
Leukemic nonnodal MCL:
- Leukemic nonnodal MCL typically develops from immunoglobulin heavy-chain variable region gene(IGHV)-mutated B cells that do not express SOX11 (SRY-Box 11 gene).[1][2]
- Leukemic nonnodal MCL involve the peripheral blood (PB), bone marrow and the spleen.
- Although these are commonly clinically indolent in nature further mutations ,especially of TP53, can lead to more aggressive disease.
In-situ mantle cell neoplasia (ISMCN):
- It is characterized by the presence of cyclin D1 positive cells mostly in the inner mantle zones of follicles in lymphoid tissues that do not otherwise suggest the diagnosis of a MCL.[3]
- The in situ lesion stage may be a common step in both SOX11-negative and positive subtypes of MCL as some in situ lesions express SOX11, whereas others are SOX11 negative.[4]
- ISMCN is often found incidentally, occasionally in association with other types of lymphomas.
References
- ↑ 1.0 1.1 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R; et al. (2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
- ↑ 2.0 2.1 Jares P, Colomer D, Campo E (2012). "Molecular pathogenesis of mantle cell lymphoma". J Clin Invest. 122 (10): 3416–23. doi:10.1172/JCI61272. PMC 3461905. PMID 23023712.
- ↑ Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY; et al. (2012). "In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior". Haematologica. 97 (2): 270–8. doi:10.3324/haematol.2011.052621. PMC 3269489. PMID 22058203.
- ↑ Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM; et al. (2010). "Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor". J Clin Oncol. 28 (31): e629–32. doi:10.1200/JCO.2010.29.8992. PMID 20733121.